{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T23:29:56Z","timestamp":1791588596380,"version":"4.3.4"},"reference-count":72,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,23]],"date-time":"2026-12-23T00:00:00Z","timestamp":1797984000000},"content-version":"am","delay-in-days":356,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100005347","name":"American Association for the Study of Liver Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000027","name":"National Institute on Alcohol Abuse and Alcoholism","doi-asserted-by":"publisher","award":["K23AA031310"],"award-info":[{"award-number":["K23AA031310"]}],"id":[{"id":"10.13039\/100000027","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000027","name":"National Institute on Alcohol Abuse and Alcoholism","doi-asserted-by":"publisher","award":["2U01AA026975"],"award-info":[{"award-number":["2U01AA026975"]}],"id":[{"id":"10.13039\/100000027","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000027","name":"National Institute on Alcohol Abuse and Alcoholism","doi-asserted-by":"publisher","award":["R01AA028791"],"award-info":[{"award-number":["R01AA028791"]}],"id":[{"id":"10.13039\/100000027","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajp.amjpathol.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Pathology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.ajpath.2025.03.009","type":"journal-article","created":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T02:34:44Z","timestamp":1744943684000},"page":"182-191","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Current Clinical Trials for Alcohol-Associated Hepatitis"],"prefix":"10.1016","volume":"196","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-5922-7912","authenticated-orcid":false,"given":"Elias D.","family":"Rady","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9488-7364","authenticated-orcid":false,"given":"Ahmad","family":"Anouti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9018-7988","authenticated-orcid":false,"given":"Mack C.","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0376-0107","authenticated-orcid":false,"given":"Thomas G.","family":"Cotter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajpath.2025.03.009_bib1","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1056\/NEJMra0805786","article-title":"Alcoholic hepatitis","volume":"360","author":"Lucey","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajpath.2025.03.009_bib2","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.cgh.2013.06.013","article-title":"Alcoholic hepatitis: current challenges and future directions","volume":"12","author":"Singal","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.ajpath.2025.03.009_bib3","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1053\/j.gastro.2016.02.042","article-title":"Standard definitions and common data elements for clinical trials in patients with alcoholic hepatitis: recommendation from the NIAAA Alcoholic Hepatitis Consortia","volume":"150","author":"Crabb","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ajpath.2025.03.009_bib4","doi-asserted-by":"crossref","first-page":"30","DOI":"10.14309\/ajg.0000000000002572","article-title":"ACG clinical guideline: alcohol-associated liver disease","volume":"119","author":"Jophlin","year":"2024","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.ajpath.2025.03.009_bib5","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/hep.30866","article-title":"Diagnosis and treatment of alcohol-associated liver diseases: 2019 practice guidance from the American Association for the Study of Liver Diseases","volume":"71","author":"Crabb","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.ajpath.2025.03.009_bib6","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1053\/j.gastro.2018.05.011","article-title":"Corticosteroids reduce risk of death within 28 days for patients with severe alcoholic hepatitis, compared with pentoxifylline or placebo\u2014a meta-analysis of individual data from controlled trials","volume":"155","author":"Louvet","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ajpath.2025.03.009_bib7","doi-asserted-by":"crossref","first-page":"311","DOI":"10.3390\/medicina60020311","article-title":"Real-world utilization of corticosteroids in severe alcoholic hepatitis: eligibility, response, and outcomes","volume":"60","author":"Singeap","year":"2024","journal-title":"Medicina (Kaunas)"},{"key":"10.1016\/j.ajpath.2025.03.009_bib8","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1056\/NEJMoa1105703","article-title":"Early liver transplantation for severe alcoholic hepatitis","volume":"365","author":"Mathurin","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajpath.2025.03.009_bib9","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0190823","article-title":"Liver transplantation for alcoholic hepatitis: a systematic review with meta-analysis","volume":"13","author":"Marot","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.ajpath.2025.03.009_bib10","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1056\/NEJMra2207599","article-title":"Alcohol-associated hepatitis","volume":"387","author":"Bataller","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajpath.2025.03.009_bib11","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.jhep.2018.10.023","article-title":"Inflammatory pathways in alcoholic steatohepatitis","volume":"70","author":"Gao","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.ajpath.2025.03.009_bib12","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0016-5085(78)90401-8","article-title":"Corticosteroid therapy of alcoholic hepatitis","volume":"75","author":"Maddrey","year":"1978","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ajpath.2025.03.009_bib13","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1136\/bmj.2.5260.1113","article-title":"Acute alcoholic hepatitis","volume":"2","author":"Beckett","year":"1961","journal-title":"Br Med J"},{"key":"10.1016\/j.ajpath.2025.03.009_bib14","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1056\/NEJM199704103361506","article-title":"Nuclear factor-kappaB\u2014a pivotal transcription factor in chronic inflammatory diseases","volume":"336","author":"Barnes","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajpath.2025.03.009_bib15","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/S0168-8278(00)80219-6","article-title":"Blood neutrophil functions and cytokine release in severe alcoholic hepatitis: effect of corticosteroids","volume":"32","author":"Ta\u00efeb","year":"2000","journal-title":"J Hepatol"},{"key":"10.1016\/j.ajpath.2025.03.009_bib16","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/S0168-8278(01)00190-8","article-title":"Rapid changes in alcoholic hepatitis histology under steroids: correlation with soluble intercellular adhesion molecule-1 in hepatic venous blood","volume":"35","author":"Spahr","year":"2001","journal-title":"J Hepatol"},{"key":"10.1016\/j.ajpath.2025.03.009_bib17","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1136\/gut.37.1.113","article-title":"Glucocorticoids are ineffective in alcoholic hepatitis: a meta-analysis adjusting for confounding variables","volume":"37","author":"Christensen","year":"1995","journal-title":"Gut"},{"key":"10.1016\/j.ajpath.2025.03.009_bib18","doi-asserted-by":"crossref","first-page":"299","DOI":"10.7326\/0003-4819-113-4-299","article-title":"Do corticosteroids reduce mortality from alcoholic hepatitis? A meta-analysis of the randomized trials.","volume":"113","author":"Imperiale","year":"1990","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ajpath.2025.03.009_bib19","doi-asserted-by":"crossref","first-page":"685","DOI":"10.7326\/0003-4819-110-9-685","article-title":"Methylprednisolone therapy in patients with severe alcoholic hepatitis. A randomized multicenter trial.","volume":"110","author":"Carithers","year":"1989","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ajpath.2025.03.009_bib20","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1053\/gast.1996.v110.pm8964410","article-title":"Survival and prognostic factors in patients with severe alcoholic hepatitis treated with prednisolone","volume":"110","author":"Mathurin","year":"1996","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ajpath.2025.03.009_bib21","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1111\/j.1365-2036.2008.03685.x","article-title":"Systematic review: glucocorticosteroids for alcoholic hepatitis\u2014a Cochrane Hepato-Biliary Group systematic review with meta-analyses and trial sequential analyses of randomized clinical trials","volume":"27","author":"Rambaldi","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.ajpath.2025.03.009_bib22","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1056\/NEJMoa1412278","article-title":"Prednisolone or pentoxifylline for alcoholic hepatitis","volume":"372","author":"Thursz","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajpath.2025.03.009_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta191020","article-title":"The clinical effectiveness and cost-effectiveness of STeroids Or Pentoxifylline for Alcoholic Hepatitis (STOPAH): a 2 \u00d7 2 factorial randomised controlled trial","volume":"19","author":"Thursz","year":"2015","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.ajpath.2025.03.009_bib24","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.jhep.2024.01.031","article-title":"Randomized trial of anakinra plus zinc vs. prednisone for severe alcohol-associated hepatitis","volume":"80","author":"Gawrieh","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.ajpath.2025.03.009_bib25","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1002\/hep.21607","article-title":"The Lille model: a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids","volume":"45","author":"Louvet","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.ajpath.2025.03.009_bib26","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/ajg.2016.539","article-title":"A day-4 Lille model predicts response to corticosteroids and mortality in severe alcoholic hepatitis","volume":"112","author":"Garcia-Saenz-de-Sicilia","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.ajpath.2025.03.009_bib27","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.jhep.2005.06.003","article-title":"Corticosteroids for alcoholic hepatitis\u2014what's next?","volume":"43","author":"Mathurin","year":"2005","journal-title":"J Hepatol"},{"key":"10.1016\/j.ajpath.2025.03.009_bib28","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1053\/j.gastro.2009.04.062","article-title":"Infection in patients with severe alcoholic hepatitis treated with steroids: early response to therapy is the key factor","volume":"137","author":"Louvet","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ajpath.2025.03.009_bib29","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1001\/jama.2021.7683","article-title":"Diagnosis and treatment of alcohol-associated liver disease","volume":"326","author":"Singal","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.ajpath.2025.03.009_bib30","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1055\/s-0039-1693402","article-title":"Assessment and management of infection in alcoholic hepatitis","volume":"40","author":"Vergis","year":"2020","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.ajpath.2025.03.009_bib31","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1053\/j.gastro.2016.12.019","article-title":"In patients with severe alcoholic hepatitis, prednisolone increases susceptibility to infection and infection-related mortality, and is associated with high circulating levels of bacterial DNA","volume":"152","author":"Vergis","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ajpath.2025.03.009_bib32","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.jhep.2018.10.026","article-title":"Current trials and novel therapeutic targets for alcoholic hepatitis","volume":"70","author":"Singal","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.ajpath.2025.03.009_bib33","article-title":"Gut dysbiosis as a driver in alcohol-induced liver injury","volume":"3","author":"Fairfield","year":"2021","journal-title":"JHEP Rep"},{"key":"10.1016\/j.ajpath.2025.03.009_bib34","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1111\/liv.15207","article-title":"Effect of rifaximin on infections, acute-on-chronic liver failure and mortality in alcoholic hepatitis: a pilot study (RIFA-AH)","volume":"42","author":"Jim\u00e9nez","year":"2022","journal-title":"Liver Int"},{"key":"10.1016\/j.ajpath.2025.03.009_bib35","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1001\/jama.2023.4902","article-title":"Effect of prophylactic antibiotics on mortality in severe alcohol-related hepatitis","volume":"329","author":"Louvet","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.ajpath.2025.03.009_bib36","doi-asserted-by":"crossref","DOI":"10.14309\/ctg.0000000000000306","article-title":"No effect in alcoholic hepatitis of gut-selective, broad-spectrum antibiotics on bacterial translocation or hepatic and systemic inflammation","volume":"12","author":"St\u00f8y","year":"2021","journal-title":"Clin Transl Gastroenterol"},{"key":"10.1016\/j.ajpath.2025.03.009_bib37","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1097\/MEG.0000000000000458","article-title":"Effects of probiotics (cultured Lactobacillus subtilis\/Streptococcus faecium) in the treatment of alcoholic hepatitis: randomized-controlled multicenter study","volume":"27","author":"Han","year":"2015","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.ajpath.2025.03.009_bib38","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.jceh.2022.01.001","article-title":"Long-term outcomes of stool transplant in alcohol-associated hepatitis-analysis of clinical outcomes, relapse, gut microbiota and comparisons with standard care","volume":"12","author":"Philips","year":"2022","journal-title":"J Clin Exp Hepatol"},{"key":"10.1016\/j.ajpath.2025.03.009_bib39","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s12072-022-10312-z","article-title":"Fecal microbiota transplantation in alcohol-associated acute-on-chronic liver failure: an open-label clinical trial","volume":"16","author":"Sharma","year":"2022","journal-title":"Hepatol Int"},{"key":"10.1016\/j.ajpath.2025.03.009_bib40","first-page":"S237","article-title":"Fecal microbiota therapy is a safe and effective option in steroid ineligible alcoholic hepatitis (FEMTAH Trial): a RCT","volume":"80","author":"Khajuria","year":"2024","journal-title":"Hepatology"},{"key":"10.1016\/j.ajpath.2025.03.009_bib41","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1089\/jmf.2007.0613","article-title":"Bovine colostrum prevents bacterial translocation in an intestinal ischemia\/reperfusion-injured rat model","volume":"12","author":"Choi","year":"2009","journal-title":"J Med Food"},{"key":"10.1016\/j.ajpath.2025.03.009_bib42","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1186\/s13063-023-07505-8","article-title":"A multicenter double-blind, placebo-controlled randomized trial to evaluate the safety and efficacy of bovine colostrum in the treatment of severe alcoholic hepatitis (SAH)","volume":"24","author":"Sidhu","year":"2023","journal-title":"Trials"},{"key":"10.1016\/j.ajpath.2025.03.009_bib43","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/s41586-019-1742-x","article-title":"Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease","volume":"575","author":"Duan","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.ajpath.2025.03.009_bib44","doi-asserted-by":"crossref","first-page":"G497","DOI":"10.1152\/ajpgi.00171.2004","article-title":"Recent advances in alcoholic liver disease. IV. Dysregulated cytokine metabolism in alcoholic liver disease","volume":"287","author":"McClain","year":"2004","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.ajpath.2025.03.009_bib45","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1053\/j.gastro.2008.08.057","article-title":"A randomized, double-blinded, placebo-controlled multicenter trial of Etanercept in the treatment of alcoholic hepatitis","volume":"135","author":"Boetticher","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ajpath.2025.03.009_bib46","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1002\/hep.20206","article-title":"A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis","volume":"39","author":"Naveau","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.ajpath.2025.03.009_bib47","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0171-2985(11)80356-6","article-title":"Inhibition of endogenous TNF formation by pentoxifylline","volume":"187","author":"Zabel","year":"1993","journal-title":"Immunobiology"},{"key":"10.1016\/j.ajpath.2025.03.009_bib48","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1053\/gast.2000.20189","article-title":"Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial","volume":"119","author":"Akriviadis","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ajpath.2025.03.009_bib49","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.jhep.2007.10.010","article-title":"Early switch to pentoxifylline in patients with severe alcoholic hepatitis is inefficient in non-responders to corticosteroids","volume":"48","author":"Louvet","year":"2008","journal-title":"J Hepatol"},{"key":"10.1016\/j.ajpath.2025.03.009_bib50","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.jhep.2014.05.014","article-title":"Pentoxifylline vs. corticosteroid to treat severe alcoholic hepatitis: a randomised, non-inferiority, open trial","volume":"61","author":"Park","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.ajpath.2025.03.009_bib51","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1111\/liv.13430","article-title":"Interleukin-1 inhibition facilitates recovery from liver injury and promotes regeneration of hepatocytes in alcoholic hepatitis in mice","volume":"37","author":"Iracheta-Vellve","year":"2017","journal-title":"Liver Int"},{"key":"10.1016\/j.ajpath.2025.03.009_bib52","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1002\/hep.32478","article-title":"IL-1 receptor antagonist plus pentoxifylline and zinc for severe alcohol-associated hepatitis","volume":"76","author":"Szabo","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.ajpath.2025.03.009_bib53","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.cgh.2024.07.025","article-title":"IL-1 signal inhibition in alcohol-related hepatitis: a randomized, double-blind, placebo-controlled trial of canakinumab","volume":"23","author":"Vergis","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.ajpath.2025.03.009_bib54","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nrgastro.2015.35","article-title":"Alcoholic liver disease: mechanisms of injury and targeted treatment","volume":"12","author":"Louvet","year":"2015","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.ajpath.2025.03.009_bib55","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa1101214","article-title":"Glucocorticoids plus N-acetylcysteine in severe alcoholic hepatitis","volume":"365","author":"Nguyen-Khac","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajpath.2025.03.009_bib56","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.fct.2008.10.020","article-title":"Hepatoprotective role and antioxidant capacity of pomegranate (Punica granatum) flowers infusion against trichloroacetic acid-exposed in rats","volume":"47","author":"Celik","year":"2009","journal-title":"Food Chem Toxicol"},{"key":"10.1016\/j.ajpath.2025.03.009_bib57","doi-asserted-by":"crossref","first-page":"13037","DOI":"10.1074\/jbc.M101632200","article-title":"Chronic ethanol exposure potentiates lipopolysaccharide liver injury despite inhibiting Jun N-terminal kinase and caspase 3 activation","volume":"277","author":"Koteish","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ajpath.2025.03.009_bib58","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.cgh.2018.06.012","article-title":"Emricasan improves liver function in patients with cirrhosis and high model for end-stage liver disease scores compared with placebo","volume":"17","author":"Frenette","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.ajpath.2025.03.009_bib59","first-page":"1","article-title":"Oral abstracts (Abstracts 1\u2013299)","volume":"68","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.ajpath.2025.03.009_bib60","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/hep.31046","article-title":"An open-label, dose-escalation study to assess the safety and efficacy of IL-22 agonist F-652 in patients with alcohol-associated hepatitis","volume":"72","author":"Arab","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.ajpath.2025.03.009_bib61","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/hep.30516","article-title":"Efficacy of granulocyte colony-stimulating factor in the management of steroid-nonresponsive severe alcoholic hepatitis: a double-blind randomized controlled trial","volume":"70","author":"Shasthry","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.ajpath.2025.03.009_bib62","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1016\/j.jhep.2021.07.033","article-title":"Granulocyte-colony stimulating factor (G-CSF) to treat acute-on-chronic liver failure: a multicenter randomized trial (GRAFT study)","volume":"75","author":"Engelmann","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.ajpath.2025.03.009_bib63","doi-asserted-by":"crossref","first-page":"107","DOI":"10.14309\/ajg.0000000000002275","article-title":"Safety, pharmacokinetics, and efficacy signals of larsucosterol (DUR-928) in alcohol-associated hepatitis","volume":"119","author":"Hassanein","year":"2024","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.ajpath.2025.03.009_bib64","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/s41575-024-00936-x","article-title":"Designing clinical trials to address alcohol use and alcohol-associated liver disease: an expert panel consensus statement","volume":"21","author":"Lee","year":"2024","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.ajpath.2025.03.009_bib65","series-title":"Alcohol-associated hepatitis remains a highly fatal condition: results from a contemporary prospective multicenter cohort study from the United States. The Liver Meeting","author":"Dasarathy","year":"2024"},{"key":"10.1016\/j.ajpath.2025.03.009_bib66","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000409","article-title":"Racial and ethnic disparities in alcohol-associated liver disease in the United States: A systematic review and meta-analysis","volume":"8","author":"Anouti","year":"2024","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.ajpath.2025.03.009_bib67","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.jhep.2018.11.005","article-title":"Endpoints and patient stratification in clinical trials for alcoholic hepatitis","volume":"70","author":"Mathurin","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.ajpath.2025.03.009_bib68","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1053\/j.gastro.2015.04.044","article-title":"Combining data from liver disease scoring systems better predicts outcomes of patients with alcoholic hepatitis","volume":"149","author":"Louvet","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ajpath.2025.03.009_bib69","doi-asserted-by":"crossref","DOI":"10.1016\/j.cct.2024.107437","article-title":"Development and evaluation of objective trial performance metrics for multisite clinical studies: Experience from the AlcHep Network","volume":"138","author":"Dasarathy","year":"2024","journal-title":"Contemp Clin Trials"},{"key":"10.1016\/j.ajpath.2025.03.009_bib70","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.jhep.2019.12.023","article-title":"Long-term outcomes in patients with decompensated alcohol-related liver disease, steatohepatitis and Maddrey\u2019s discriminant function <32","volume":"72","author":"Degr\u00e9","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.ajpath.2025.03.009_bib71","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.jhep.2017.09.013","article-title":"Controversies in clinical trials for alcoholic hepatitis","volume":"68","author":"Lieber","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.ajpath.2025.03.009_bib72","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1055\/a-2000-6680","article-title":"The changing epidemiology of alcohol-associated liver disease: gender, race, and risk factors","volume":"43","author":"Anouti","year":"2023","journal-title":"Semin Liver Dis"}],"container-title":["The American Journal of Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002944025001166?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002944025001166?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:47:16Z","timestamp":1777376836000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002944025001166"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":72,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S0002944025001166"],"URL":"https:\/\/doi.org\/10.1016\/j.ajpath.2025.03.009","relation":{},"ISSN":["0002-9440"],"issn-type":[{"value":"0002-9440","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current Clinical Trials for Alcohol-Associated Hepatitis","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajpath.2025.03.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society for Investigative Pathology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}